BioXcel Therapeutics, Inc. (BTAI) Retains Buy Rating on Positive Trial Progress
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) is among the fundamentally strong penny stocks to invest in. H.C. Wainwright analysts have reiterated their Buy rating on BioXcel Therapeutics, Inc.